Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Paul Barr who wrote (4089)	4/16/1998 8:10:00 PM
From: Clive Roberts	Read Replies (1) of 6136

I agree. Something that isn't included in Balance Sheets is leadership. Agouron have exceeded expectations measured against anything Johnson has said at previous conference calls. They have produced an absolute success story. I've been long since Oct 96. It is true that there is a lull between their first drug to market and their second. But I respect the fact that they exited Thymitaq when they did rather than waste money going to Phase III. They recognised they had better drugs to spend their money on. The market will start to factor in 3340 and additonial pipeline soon enough. Now is probably the time to beat them to it. Fundamentally.... the company delivers. My money is staying in.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next